Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Regencell Bioscience Holdings EV-to-EBITDA?
Regencell Bioscience HoldingsRGC -6.02%31 EV-to-EBITDA is -389.05 as of Jul. 23, 2026. GuruFocus rates RGC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 743 Drug Manufacturers companies, Regencell Bioscience Holdings ranks worse than 134589.37% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Regencell Bioscience Holdings's enterprise value is $2,774.67 Mil.
Regencell Bioscience Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.13 Mil. Therefore, Regencell Bioscience Holdings's EV-to-EBITDA for today is -389.05.
The historical rank and industry rank for Regencell Bioscience Holdings's EV-to-EBITDA or its related term are showing as below:
RGC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -414.01 Med: 0 Max: 0
Current: -389.05
RGC's EV-to-EBITDA is ranked worse than 100% of 743
companies
in the Drug Manufacturers industry
Industry Median: 13.02
vs RGC: -389.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regencell Bioscience Holdings's PE Ratio (TTM) for today is calculated as:
Regencell Bioscience Holdings's share price for today is $5.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regencell Bioscience Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's EV-to-EBITDA falls into.
Regencell Bioscience Holdings's current Enterprise Value is $2,774.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regencell Bioscience Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regencell Bioscience Holdings (RGC) has a EV-to-EBITDA of -389.05 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regencell Bioscience Holdings. According to the industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 743 companies in the Drug Manufacturers industry.
Is Regencell Bioscience Holdings' EV-to-EBITDA too high?
Regencell Bioscience Holdings' current EV-to-EBITDA is -389.05. Based on the distribution chart, Regencell Bioscience Holdings ranks #999999 out of 743 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regencell Bioscience Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' EV-to-EBITDA compare to SUPN and BCRX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 743 companies for EV-to-EBITDA. This places Regencell Bioscience Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regencell Bioscience Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current EV-to-EBITDA is -389.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current EV-to-EBITDA of -389.05. The current EV-to-EBITDA is -389.05. Regencell Bioscience Holdings' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current EV-to-EBITDA is -389.05 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regencell Bioscience Holdings Business Description
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
31GF Score
Get the complete analysis for RGC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGC has been successfully added to your 
